Stimulation of Sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 11, 2009, Pages 1253-1265

  Bhuiyan, Md Shenuarin ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

dehydroepiandrosterone (DHEA); endothelial nitric oxide synthase (eNOS); myocardial hypertrophy; ovariectomy; protein kinase B (Akt); Sigma 1 receptor (Sig 1R)

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; PRASTERONE; PROTEIN KINASE B; SIGMA 1 OPIATE RECEPTOR; CARDIOTONIC AGENT; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; AORTA STENOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OVERLOAD; HEART PROTECTION; HEART RIGHT VENTRICLE; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; METABOLISM; OVARIECTOMY; SIGNAL TRANSDUCTION; TIME; UPREGULATION; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 73449138826     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728220903264064     Document Type: Article

References (47)

1. Tannenbaum C, Barrett-Connor E, Laughlin GA, et al. A longitudinal study of dehydroepiandrosterone sulphate (DHEAS) change in older men and women: the Rancho Bernardo Study Eur J Endocrinol 2004;151:717-25 (Pubitemid 40090011)
2. Akishita M, Hashimoto M, Ohike Y, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res 2008;31:69-74 (Pubitemid 351325617)
3. Bernini GP, Sgro' M, Moretti A, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999;84:2008-12 (Pubitemid 30647026)
4. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J Clin Endocrinol Metab 2005;90:4836-45 (Pubitemid 41159380)
5. Barna I, Feher T, de Chatel R. Relationship between blood pressure variability and serum dehydroepiandrosterone sulfate levels. Am J Hypertens 1998;11:532-8 (Pubitemid 28270713)
6. Haffner SM, Moss SE, Klein BE, et al. Sex hormones and DHEA-SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1996;19:1045-50 (Pubitemid 26334250)
7. Szathmári M, Treszl A, Vásárhelyi B. Left ventricular mass index and ventricular septum thickness are associated with serum dehydroepiandrosterone-sulphate Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52
8. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann NY Acad Sci 1995;774:271-80 (Pubitemid 26140376)
9. Mortola JF, Yen SCC. The effects of oral dehydroepiandrosterone on endocrine-metabolic in postmenopausal women. J Clin Endocrinol Metab 1990;71(3):696-704
10. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women.Eur J Endocrinol 2001;145:457-61 (Pubitemid 32927074)
11. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003;88:3190-5 (Pubitemid 36877493)
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
13. Pluchino N, Ninni F, Stomati M, et al. One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas 2008;59(4):293-303
14. Genazzani AD, Lanzoni C, Genazzani AR Might DHEA be a benefcial replacement therapy in the elderly? Drugs Aging 2007;24(3):173-85 (Pubitemid 46457022)
15. Hinson JP, Raven PW. DHEA defciency syndrome: a new term for old age? J Endocrinol 1999;163:1-5 (Pubitemid 29481296)
16. Hayashi T, Esaki T, Muto E, et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen : the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000;20:782-92 (Pubitemid 30151694)
17. Simoncini T, Mannella P, Fornari L, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinol 2003;144:3449-55 (Pubitemid 36904421)
18. Leblanc M, Labrie C, Belanger A, et al. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J Ster Biochem Mol Biol 2002;81:159-64 (Pubitemid 34879140)
19. Labrie F, Belanger L, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not refected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82:2403-9 (Pubitemid 27337847)
20. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specifc plasma membrane receptor coupled to Gai2,3. J Biol Chem 2002;277:21379-88 (Pubitemid 34952278)
21. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004;69:279-89 (Pubitemid 38748724)
22. Liu D, Si H, Reynolds KA, et al. Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through Goti protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinol 2007;148(7):3068-76 (Pubitemid 46996987)
23. Ueda H, Yoshida A, Tokuyama S, et al. Neurosteroids stimulate G protein-coupled sigma receptors in mouse brain synaptic membrane. Neurosci Res 2001;41:33-40 (Pubitemid 32776634)
24. Maurice T, Gregoire C, Espallergues J. Neuro(active)steroids actions at the neuromodulatory sigma1 ((71) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 2006;84:581-97 (Pubitemid 350061234)
25. Cheng ZX, Lan DM, Wu PY, et al. Neurosteroid dehydroepiandrosterone sulphate inhibits persistent sodium currents in rat medial prefrontal cortex via activation of sigma-1 receptors. Exp Neurol 2008;210:128-36
26. Morin-Surun MP, Colin T, Denavit-Saubie M, et al. Intracellular C71 receptor modulates phospholipase C and protein kinase C activities in brainstem. Proc Natl Acad Sci USA 1999;96:8196-9 (Pubitemid 29328431)
27. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 2007;293:E1606-14 (Pubitemid 350255110)
28. Bhuiyan MS, Shioda N, Shibuya M, et al. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 2009;53(1):57-63
29. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington DC. National Academy Press; 1996
30. Bhuiyan MS, Shioda N, Fukunaga K. Chronic [-adrenoceptor activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats. Expert Opin Ther Targets 2009;13:275-86
31. Yamada J, Sakuma M, Suga T. Assay of fatty acid (O-hydroxylation using high performance liquid chromatography with fuorescence labeling reagent, 3-bromomethyl-7-methoxy-1, 4-benzoxazin-2-one (BrMB). Anal Biochem 1991;199:132-6
32. Dobonneuil EH, Quillard J, Baulieu EE. Hypoxia and dehydroepiandrosterone in old age: a mouse survival study. Respir Res 2006;7:144. Published online 18 December 2006, doi:10.1186/1465-9921-7-144
33. Bonnet S, Dumas-de-La-Roque E, Bégueret H, et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 2003;100(16):9488-93 (Pubitemid 37033955)
34. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;88:3147-51
35. Longcope C. The metabolism of DHEA. In: Dehydroepiandrosterone (DHEA) and aging. Ann NY Acad Sci 1995;774:143-8
36. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-45 (Pubitemid 30180890)
37. Fulton D, Gratton J-P, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-24 (Pubitemid 33104947)
38. Wang L, Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp Cell Res 2006;312(8):1439-46
39. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the (7-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004;64(14):4875-86 (Pubitemid 38924532)
40. Williams MR, Ling S, Dawood T, et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002;87:176-81 (Pubitemid 34084688)
41. Zapata E, Ventura JL, De la Cruz K, et al. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen-and estrogen-receptor independent. FEBS J 2005;272:1343-53 (Pubitemid 40444925)
42. Houser SR, Molkentin JD. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci Signal 2008;1(25):pe31. Published online 24 June 2008, doi: 10.1126/scisignal.125pe31
43. Monnet F P. Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell 2005;97(12):873-83 (Pubitemid 41819305)
44. Tchedre KT, Huang RQ, Dibas A, et al. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci 2008;49(11):4993-5002
45. Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003;21:346-55 (Pubitemid 44175250)
46. Genazzani AD, Stomati M, Bernardi F, et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal woman modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003;80:1495-501 (Pubitemid 37532468)
47. Swierczynski J, Mayer D. Dehydroepiandrosterone-induced lipid peroxidation in rat liver mitochondria. J Steroid Biochem Mol Biol 1996;58:599-603 (Pubitemid 126657507)